Evidence map›Paper›PMID 38183597›Full record

SynthesisObesity surgery2024

Efficacy of High-dose Liraglutide 3.0 mg in Patients with Poor Response to Bariatric Surgery: Real-world Experience and Updated Meta-analysis.

Federica Vinciguerra, Carla Di Stefano, Roberto Baratta, Alfredo Pulvirenti, Giuseppe Mastrandrea, Luigi Piazza, Fabio Guccione, Giuseppe Navarra, Lucia Frittitta

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Obesity surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 4 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Observational
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Federica VinciguerraDepartment of Clinical and Experimental Medicine, University of Catania, Via Santa Sofia, 89, 95123, Catania, Italy. vinciguerrafederica@gmail.com.ORCID 0000-0001-9916-4272
Carla Di StefanoGeneral and Emergency Surgery Department, Garibaldi Hospital, 95122, Catania, Italy.
Roberto BarattaEndocrinology Unit, Garibaldi Hospital, 95122, Catania, Italy.
Alfredo PulvirentiBioinformatics Unit, Department of Clinical and Experimental Medicine, University of Catania, 95131, Catania, Italy.
Giuseppe MastrandreaBariatric Surgery Unit, Candela Clinic, 90141, Palermo, Italy.
Luigi PiazzaGeneral and Emergency Surgery Department, Garibaldi Hospital, 95122, Catania, Italy.
Fabio GuccioneDepartment of Human Pathology, University of Messina, 98122, Messina, Italy.
Giuseppe NavarraDepartment of Human Pathology, University of Messina, 98122, Messina, Italy.
Lucia FrittittaDepartment of Clinical and Experimental Medicine, University of Catania, Via Santa Sofia, 89, 95123, Catania, Italy.
Ospedale Garibaldi · ITUniversity of Catania · ITUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePoor response to bariatric surgery, characterized by insufficient weight loss (IWL) or weight regain (WR), poses a significant challenge in obesity treatment. This study aims to assess the effectiveness of liraglutide in addressing this issue. MATERIALS AND

methodsA retrospective, multicenter cohort study investigated the impact of liraglutide 3 mg on weight loss in adults with suboptimal responses or weight regain after bariatric surgery (BS). Additionally, a systematic review and meta-analysis were conducted for a comprehensive evaluation.

resultsA total of 119 patients (mean age 41.03 ± 11.2 years, 71.4% female) who experienced IWL or WR after BS received pharmacologic therapy with liraglutide 3 mg. Mean percent weight loss in the entire cohort was 5.6 ± 2.6% at 12 weeks and 9.3 ± 3.6% at 24 weeks with a significant reduction in waist circumference (p < 0.0001). No serious side effects were reported. A meta-analysis, utilizing the fixed effect model with the metafor package in R, included 6 and 5 papers for the change in body weight and BMI after liraglutide treatment, respectively. The analysis demonstrated a considerable reduction in body weight (7.9; CI - 10.4; - 5.4, p < 0.0001) and BMI (3.09; CI 3.89; - 2.28, p < 0.0001).

conclusionLiraglutide 3 mg emerges as a viable option for significant weight loss in patients experiencing IWL or WR after BS. Its inclusion in a multimodal, sequential obesity treatment approach proves promising.

Indexed as

Bariatric SurgeryLiraglutideAdultCohort StudiesFemaleHumansMaleMiddle AgedObesityRetrospective StudiesWeight GainWeight LossLiraglutideBariatric surgeryInsufficient weight lossLiraglutideWeight regain

Identifiers

PMID38183597
PMCPMC10811090
OpenAlexW4390638282

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.